SAN FRANCISCO, Nov. 21, 2025 (GLOBE NEWSWIRE) -- MoonLake Immunotherapeutics (NASDAQ: MLTX), a clinical-stage biotechnology company, has been hit with a securities fraud class action lawsuit after its share price plummeted nearly 90% in a single day. The sharp decline was triggered by the release of disappointing Phase 3 trial results for its lead and only drug candidate, sonelokimab (SLK). Global plaintiffs’ rights firm Hagens Berman is actively investigating the alleged claims. The firm urges investors in ...

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages MoonLake Immunotherapeutics Investors to Secure Counsel Before Important Deadline in Securities Class Action - MLTXNovember 21, 2025 2:16 PM EST | Source: The Rosen Law Firm PANew York, New York--(Newsfile Corp. - November 21, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2024 and September 29, 2025, both dates inclusive (the "Class Pe ...

James (Josh) Wilson, Faruqi & Faruqi Senior Partner (PRNewsfoto/Faruqi & Faruqi, LLP) Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com. As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose th ...

Accessibility StatementSkip Navigation CONTACT:Levi & Korsinsky, LLP Joseph E. Levi, Esq.Ed Korsinsky, Esq.33 Whitehall Street, 27th FloorNew York, NY 10004[email protected] Tel: (212) 363-7500Fax: (212) 363-7171www.zlk.com SOURCE Levi & Korsinsky, LLP CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of MoonLake investors who were adversely affected by alleged securities fraud between March 10, 2024 and September 29, 2025. Follow the link below to get more information and be contacted by a ...

NEW YORK, Nov. 21, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against MoonLake Immunotherapeutics (NASDAQ: MLTX) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in MoonLake, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/moonlake-immunotherapeutics-class-action-lawsuit. Investors have until December 15, 2025, to as ...

NEW YORK, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in MoonLake Immunotherapeutics ("MoonLake" or the "Company") (NASDAQ: MLTX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of MoonLake investors who were adversely affected by alleged securities fraud between March 10, 2024 and September 29, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/moonlake-law ...

MLTX INVESTORS: BFA Law Reminds MoonLake Immunotherapeutics Investors with Losses to Contact the Firm Before the Imminent December 15 Securities Class Action DeadlineNovember 20, 2025 3:46 PM EST | Source: Bleichmar Fonti & AuldNew York, New York--(Newsfile Corp. - November 20, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against MoonLake Immunotherapeutics (NASDAQ: MLTX) and certain of the Company's senior executives for potential viol ...

文章核心观点 - Rosen Law Firm提醒在2024年3月10日至2025年9月29日期间购买MoonLake Immunotherapeutics普通股的投资者，关于一项证券集体诉讼的重要截止日期是2025年12月15日 [2] 诉讼案件细节 - 诉讼指控被告在整个集体诉讼期间就Nanobodies与单克隆抗体的区别做出虚假和/或误导性陈述，并且未能披露重要事实 [6] - 具体指控包括：SLK和BIMZELX拥有相同的分子靶点；SLK独特的纳米抗体结构不会带来优于BIMZELX传统单克隆结构的临床益处；SLK纳米抗体结构假定的组织渗透性不会转化为临床疗效 [6] - 基于上述情况，指控认为被告对其关于SLK优于单克隆抗体的积极陈述缺乏合理依据 [6] 律所背景信息 - Rosen Law Firm是一家在全球范围内代表投资者的律所，专注于证券集体诉讼和股东衍生诉讼 [5] - 该律所在2017年被ISS证券集体诉讼服务评为和解案件数量第一名，自2013年以来每年排名前四 [5] - 该律所为投资者追回数亿美元，仅在2019年就为投资者确保了超过4.38亿美元 [5]

Accessibility StatementSkip Navigation NEW YORK, Nov. 20, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of MoonLake Immunotherapeutics (NASDAQ: MLTX). SOURCE The Gross Law Firm CONTACT US HERE: https://securitiesclasslaw.com/securities/moonlake-loss-submission-form/?id=178116&from=4 CLASS PERIOD: March 10, 2024 to September 29, 2025 ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or fai ...

集体诉讼案件核心信息 - Rosen Law Firm提醒在2024年3月10日至2025年9月29日期间购买MoonLake Immunotherapeutics普通股的投资者，首席原告截止日期为2025年12月15日 [1] - 投资者可能有权通过风险代理收费安排获得补偿，无需支付任何自付费用 [2] 诉讼案件指控细节 - 指控被告在整个集体诉讼期间就Nanobodies与单克隆抗体的区别做出虚假和/或误导性陈述，且未披露重要事实 [5] - 具体指控包括：SLK和BIMZELX具有相同的分子靶点；SLK的Nanobody结构不会带来优于BIMZELX单克隆结构的临床效益；其组织渗透性不会转化为临床疗效；基于此，被告对其SLK优于单克隆抗体的正面陈述缺乏合理依据 [5] - 当真实情况被市场知悉后，投资者遭受了损失 [5] 律所背景与资质 - Rosen Law Firm是一家在全球代表投资者的律所，专注于证券集体诉讼和股东衍生诉讼 [4] - 该律所曾达成针对中国公司的史上最大证券集体诉讼和解，并被ISS Securities Class Action Services评为2017年证券集体诉讼和解数量第一 [4] - 自2013年以来，该律所每年排名均在前四，并为投资者追回数亿美元，仅在2019年就为投资者确保了超过4.38亿美元 [4]